SK12932001A3 - Farmaceutická kompozícia na prevenciu alebo liečenie choroby spojenej s nadmernou produkciou IL-12 - Google Patents

Farmaceutická kompozícia na prevenciu alebo liečenie choroby spojenej s nadmernou produkciou IL-12 Download PDF

Info

Publication number: SK12932001A3
Authority: SK; Slovakia
Prior art keywords: methyl; oxo; phenyl; dihydro; quinazolin
Prior art date: 2000-09-15

Application number

SK1293-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Corinne Moulon

Heleen Heysteck

Original Assignee

Warner-Lambert Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-15

Filing date

2001-09-11

Publication date

2002-04-04

2001-09-11 Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company

2002-04-04 Publication of SK12932001A3 publication Critical patent/SK12932001A3/sk

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 28
201000010099 disease Diseases 0.000 title claims abstract description 27
230000019734 interleukin-12 production Effects 0.000 title claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 title claims description 4
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims abstract description 76
239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims abstract description 76
150000003839 salts Chemical class 0.000 claims abstract description 12
238000004519 manufacturing process Methods 0.000 claims abstract description 11
239000003814 drug Substances 0.000 claims abstract description 10
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 17
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 17
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 16
150000001875 compounds Chemical class 0.000 claims description 15
108010065805 Interleukin-12 Proteins 0.000 claims description 14
102000013462 Interleukin-12 Human genes 0.000 claims description 14
230000002757 inflammatory effect Effects 0.000 claims description 13
206010003246 arthritis Diseases 0.000 claims description 12
230000001363 autoimmune Effects 0.000 claims description 12
230000001684 chronic effect Effects 0.000 claims description 12
HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical group COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims description 12
229950005741 rolipram Drugs 0.000 claims description 12
239000003112 inhibitor Substances 0.000 claims description 11
CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 claims description 10
239000000825 pharmaceutical preparation Substances 0.000 claims description 10
230000002265 prevention Effects 0.000 claims description 10
208000027866 inflammatory disease Diseases 0.000 claims description 9
238000012261 overproduction Methods 0.000 claims description 7
CRHOJTLKLUQJSM-UHFFFAOYSA-N pyrazolo[3,4-d]diazepine Chemical class C1=NN=CC=C2C=NN=C21 CRHOJTLKLUQJSM-UHFFFAOYSA-N 0.000 claims description 7
208000028867 ischemia Diseases 0.000 claims description 6
230000000414 obstructive effect Effects 0.000 claims description 6
BSYFXFLGOGQHFU-UHFFFAOYSA-N pyrrolo[2,3-g][1,2]benzodiazepine Chemical class N1=NC=CC=C2C3=NC=CC3=CC=C21 BSYFXFLGOGQHFU-UHFFFAOYSA-N 0.000 claims description 6
201000006417 multiple sclerosis Diseases 0.000 claims description 5
230000001575 pathological effect Effects 0.000 claims description 5
208000016192 Demyelinating disease Diseases 0.000 claims description 4
206010061218 Inflammation Diseases 0.000 claims description 4
230000001154 acute effect Effects 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
201000002491 encephalomyelitis Diseases 0.000 claims description 4
230000004054 inflammatory process Effects 0.000 claims description 4
230000000968 intestinal effect Effects 0.000 claims description 4
230000001404 mediated effect Effects 0.000 claims description 4
230000009885 systemic effect Effects 0.000 claims description 4
VQZRVPWIZFFSQD-UHFFFAOYSA-N 6h-quinazolin-5-one Chemical class C1=NC=C2C(=O)CC=CC2=N1 VQZRVPWIZFFSQD-UHFFFAOYSA-N 0.000 claims description 3
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims description 3
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
206010006482 Bronchospasm Diseases 0.000 claims description 3
206010009900 Colitis ulcerative Diseases 0.000 claims description 3
206010019663 Hepatic failure Diseases 0.000 claims description 3
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
208000034486 Multi-organ failure Diseases 0.000 claims description 3
208000010718 Multiple Organ Failure Diseases 0.000 claims description 3
208000028389 Nerve injury Diseases 0.000 claims description 3
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
206010040047 Sepsis Diseases 0.000 claims description 3
206010040070 Septic Shock Diseases 0.000 claims description 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
208000010668 atopic eczema Diseases 0.000 claims description 3
230000007885 bronchoconstriction Effects 0.000 claims description 3
208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
206010009887 colitis Diseases 0.000 claims description 3
230000002008 hemorrhagic effect Effects 0.000 claims description 3
230000001900 immune effect Effects 0.000 claims description 3
210000000936 intestine Anatomy 0.000 claims description 3
208000007903 liver failure Diseases 0.000 claims description 3
231100000835 liver failure Toxicity 0.000 claims description 3
239000002207 metabolite Chemical class 0.000 claims description 3
208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 3
230000008764 nerve damage Effects 0.000 claims description 3
201000008482 osteoarthritis Diseases 0.000 claims description 3
206010036784 proctocolitis Diseases 0.000 claims description 3
230000002685 pulmonary effect Effects 0.000 claims description 3
230000010410 reperfusion Effects 0.000 claims description 3
230000036303 septic shock Effects 0.000 claims description 3
208000013223 septicemia Diseases 0.000 claims description 3
YPZARNMVEFFLNZ-UHFFFAOYSA-N 1,10-diazatricyclo[6.4.1.04,13]trideca-2,4(13),5,7,9,11-hexaene Chemical class C1=CN=CC2=CC=CC3=C2N1C=C3 YPZARNMVEFFLNZ-UHFFFAOYSA-N 0.000 claims description 2
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 2
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 2
210000000621 bronchi Anatomy 0.000 claims description 2
150000002475 indoles Chemical class 0.000 claims description 2
206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
206010006451 bronchitis Diseases 0.000 claims 4
206010039491 Sarcoma Diseases 0.000 claims 3
201000004624 Dermatitis Diseases 0.000 claims 2
206010012442 Dermatitis contact Diseases 0.000 claims 2
206010014561 Emphysema Diseases 0.000 claims 2
206010033645 Pancreatitis Diseases 0.000 claims 2
206010033647 Pancreatitis acute Diseases 0.000 claims 2
201000003229 acute pancreatitis Diseases 0.000 claims 2
208000010247 contact dermatitis Diseases 0.000 claims 2
210000002249 digestive system Anatomy 0.000 claims 2
208000019423 liver disease Diseases 0.000 claims 2
208000027775 Bronchopulmonary disease Diseases 0.000 claims 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
201000004681 Psoriasis Diseases 0.000 claims 1
-1 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro- [1,4] diazepino [6,7,1-hi] indole-3- yl Chemical group 0.000 description 88
210000004443 dendritic cell Anatomy 0.000 description 64
210000004027 cell Anatomy 0.000 description 32
230000000694 effects Effects 0.000 description 22
230000035800 maturation Effects 0.000 description 17
102000004127 Cytokines Human genes 0.000 description 15
108090000695 Cytokines Proteins 0.000 description 15
210000001744 T-lymphocyte Anatomy 0.000 description 13
KCKIKSJECTZLJA-UHFFFAOYSA-N indol-4-one Chemical compound O=C1C=CC=C2N=CC=C12 KCKIKSJECTZLJA-UHFFFAOYSA-N 0.000 description 13
229940117681 interleukin-12 Drugs 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
238000000034 method Methods 0.000 description 11
230000002401 inhibitory effect Effects 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
230000016396 cytokine production Effects 0.000 description 8
GSXVPNLAOHBBKA-UHFFFAOYSA-N 2-methyl-3-(6-methyl-12-oxo-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-11-yl)-4-oxoquinazoline-7-carboxylic acid Chemical compound C=1C(C)=CC=2CCN(C(C(N=3)N4C(C5=CC=C(C=C5N=C4C)C(O)=O)=O)=O)C=2C=1C=3C1=CC=CC=C1 GSXVPNLAOHBBKA-UHFFFAOYSA-N 0.000 description 7
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 7
239000002775 capsule Substances 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 7
239000000203 mixture Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
108090000978 Interleukin-4 Proteins 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
239000003826 tablet Substances 0.000 description 6
108010029697 CD40 Ligand Proteins 0.000 description 5
102100032937 CD40 ligand Human genes 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
238000000684 flow cytometry Methods 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
239000000843 powder Substances 0.000 description 5
230000028327 secretion Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
208000023275 Autoimmune disease Diseases 0.000 description 4
108090001005 Interleukin-6 Proteins 0.000 description 4
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 4
230000011748 cell maturation Effects 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
230000006698 induction Effects 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 4
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
LTJCKJVQPRZVDG-UHFFFAOYSA-N 3h-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=CC=C2C(O)=NC3=NN=CN3C2=C1 LTJCKJVQPRZVDG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
101150013553 CD40 gene Proteins 0.000 description 3
102100035793 CD83 antigen Human genes 0.000 description 3
WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 3
102100037850 Interferon gamma Human genes 0.000 description 3
108090000467 Interferon-beta Proteins 0.000 description 3
108010074328 Interferon-gamma Proteins 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
230000028993 immune response Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
239000006187 pill Substances 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
239000000829 suppository Substances 0.000 description 3
238000007910 systemic administration Methods 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
XJRJIWSZIGSBKC-UHFFFAOYSA-N 1-(azepan-1-yl)-7-bromo-4-[(3,4-dimethoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=C(OC)C(OC)=CC=C1CN1C(=O)C2=CC(Br)=CC=C2N2C(N3CCCCCC3)=NN=C21 XJRJIWSZIGSBKC-UHFFFAOYSA-N 0.000 description 2
ZQXXKVZZZNEMJN-UHFFFAOYSA-N 1-(azepan-1-yl)-7-chloro-4-(pyridin-3-ylmethyl)-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C=1C(Cl)=CC=C(N2C(N3CCCCCC3)=NN=C22)C=1C(=O)N2CC1=CC=CN=C1 ZQXXKVZZZNEMJN-UHFFFAOYSA-N 0.000 description 2
RSCOXRGQDBDAFH-UHFFFAOYSA-N 1-(azepan-1-yl)-7-chloro-4-[(3,4-dimethoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=C(OC)C(OC)=CC=C1CN1C(=O)C2=CC(Cl)=CC=C2N2C(N3CCCCCC3)=NN=C21 RSCOXRGQDBDAFH-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
FZKOUTKAKUPEED-UHFFFAOYSA-N 3-butan-2-yl-1-propyl-5-pyridin-4-yl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CCC)N=C(C(C)CC)C=2N=C1C1=CC=NC=C1 FZKOUTKAKUPEED-UHFFFAOYSA-N 0.000 description 2
ONUXVZFUVBOSGE-UHFFFAOYSA-N 3-cyclohexyl-1-ethyl-5-pyridin-4-yl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1=2N=C(C=3C=CN=CC=3)CNC(=O)C=2N(CC)N=C1C1CCCCC1 ONUXVZFUVBOSGE-UHFFFAOYSA-N 0.000 description 2
IADSMOLIAFCBCX-UHFFFAOYSA-N 3-cyclohexyl-1-propyl-5-pyridin-4-yl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1=2N=C(C=3C=CN=CC=3)CNC(=O)C=2N(CCC)N=C1C1CCCCC1 IADSMOLIAFCBCX-UHFFFAOYSA-N 0.000 description 2
GDXLUSSAJYVVIV-UHFFFAOYSA-N 4-(1-ethyl-8-oxo-3-propan-2-yl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-5-yl)benzonitrile Chemical compound C1NC(=O)C=2N(CC)N=C(C(C)C)C=2N=C1C1=CC=C(C#N)C=C1 GDXLUSSAJYVVIV-UHFFFAOYSA-N 0.000 description 2
CGPWTNLEKSPWPH-UHFFFAOYSA-N 4-[(3,4-dimethoxyphenyl)methyl]-7-methyl-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=C(OC)C(OC)=CC=C1CN1C(=O)C2=CC(C)=CC=C2N2C(N3CCCC3)=NN=C21 CGPWTNLEKSPWPH-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
QTBVGWHCEHGDIV-UHFFFAOYSA-N 4-benzyl-7-(ethylamino)-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C=1C(NCC)=CC=C(N2C(N3CCCC3)=NN=C22)C=1C(=O)N2CC1=CC=CC=C1 QTBVGWHCEHGDIV-UHFFFAOYSA-N 0.000 description 2
DPCZJJQUOLGDOQ-UHFFFAOYSA-N 5-tert-butyl-3-propan-2-yl-1-propyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound N1=C(C(C)(C)C)CNC(=O)C2=C1C(C(C)C)=NN2CCC DPCZJJQUOLGDOQ-UHFFFAOYSA-N 0.000 description 2
FILGOEPVRQSISF-UHFFFAOYSA-N 7-bromo-1-(dimethylamino)-4-(3-phenylprop-2-ynyl)-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound O=C1C2=CC(Br)=CC=C2N2C(N(C)C)=NN=C2N1CC#CC1=CC=CC=C1 FILGOEPVRQSISF-UHFFFAOYSA-N 0.000 description 2
AXLVBRADLQEUHV-UHFFFAOYSA-N 7-bromo-4-[(3,4-dimethoxyphenyl)methyl]-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=C(OC)C(OC)=CC=C1CN1C(=O)C2=CC(Br)=CC=C2N2C(N3CCCC3)=NN=C21 AXLVBRADLQEUHV-UHFFFAOYSA-N 0.000 description 2
BURHCDIQSJCTBK-UHFFFAOYSA-N 7-bromo-4-[(4-chlorophenyl)methyl]-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)C2=CC(Br)=CC=C2N2C(N3CCCC3)=NN=C21 BURHCDIQSJCTBK-UHFFFAOYSA-N 0.000 description 2
OZSSXZCKLNINIL-UHFFFAOYSA-N 7-bromo-4-[(4-methylphenyl)methyl]-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=CC(C)=CC=C1CN1C(=O)C2=CC(Br)=CC=C2N2C(N3CCCC3)=NN=C21 OZSSXZCKLNINIL-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
FFKJIACWQDWRFK-UHFFFAOYSA-N CNC=1C=C2CN(C=3N(C2=CC1)C=NN3)C(C3=CC=C(C#N)C=C3)N3CCCC3=O Chemical compound CNC=1C=C2CN(C=3N(C2=CC1)C=NN3)C(C3=CC=C(C#N)C=C3)N3CCCC3=O FFKJIACWQDWRFK-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
102000009016 Cholera Toxin Human genes 0.000 description 2
108010049048 Cholera Toxin Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
241000206672 Gelidium Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
102000003996 Interferon-beta Human genes 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
239000000440 bentonite Substances 0.000 description 2
235000012216 bentonite Nutrition 0.000 description 2
229910000278 bentonite Inorganic materials 0.000 description 2
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
239000000833 heterodimer Substances 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000017306 interleukin-6 production Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000010212 intracellular staining Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
MQZUPFSBONILJC-UHFFFAOYSA-N methyl 2-[4-[(7-bromo-5-oxo-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-4-yl)methyl]phenyl]acetate Chemical compound C1=CC(CC(=O)OC)=CC=C1CN1C(=O)C2=CC(Br)=CC=C2N2C(N3CCCC3)=NN=C21 MQZUPFSBONILJC-UHFFFAOYSA-N 0.000 description 2
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
PJSOCBVWZJGTHW-UHFFFAOYSA-N n-(1h-indazol-5-yl)-5-[3-methoxy-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-1,3-oxazol-2-amine Chemical compound C1=C(OC)C(OCCOCCOC)=CC=C1C(O1)=CN=C1NC1=CC=C(NN=C2)C2=C1 PJSOCBVWZJGTHW-UHFFFAOYSA-N 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
230000007170 pathology Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000013589 supplement Substances 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000001993 wax Substances 0.000 description 2
YPRBAEYFBIYTLT-UHFFFAOYSA-N (1-ethyl-5-phenyl-3-propan-2-yl-6h-pyrazolo[4,3-e][1,4]diazepin-8-yl)cyanamide Chemical compound C1NC(=NC#N)C=2N(CC)N=C(C(C)C)C=2N=C1C1=CC=CC=C1 YPRBAEYFBIYTLT-UHFFFAOYSA-N 0.000 description 1
HVUUBQWZWIBQGA-SANMLTNESA-N (11S)-11-(2,6-dimethyl-4-oxoquinazolin-3-yl)-6-methyl-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound N([C@H](C(N1CCC=2C=C(C)C=C3C1=2)=O)N1C(C)=NC2=CC=C(C=C2C1=O)C)=C3C1=CC=CC=C1 HVUUBQWZWIBQGA-SANMLTNESA-N 0.000 description 1
MOEXNCSUAQSQAX-SANMLTNESA-N (11S)-11-(2,8-dimethyl-4-oxoquinazolin-3-yl)-6-methyl-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound C=1C(C)=CC=2CCN(C([C@@H](N=3)N4C(C5=CC=CC(C)=C5N=C4C)=O)=O)C=2C=1C=3C1=CC=CC=C1 MOEXNCSUAQSQAX-SANMLTNESA-N 0.000 description 1
DAJBLWXUFLHGGH-DEOSSOPVSA-N (11S)-11-(2-methyl-4-oxoquinazolin-3-yl)-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound N([C@H](C(N1CCC=2C=CC=C3C1=2)=O)N1C(=O)C2=CC=CC=C2N=C1C)=C3C1=CC=CC=C1 DAJBLWXUFLHGGH-DEOSSOPVSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
ZDKBKMBUGVPDDL-UHFFFAOYSA-N 1,12-diazatricyclo[6.4.1.04,13]trideca-2,4(13),5,7,10-pentaen-9-one Chemical compound N1C=CC(C=2C=CC=C3C=CN1C=23)=O ZDKBKMBUGVPDDL-UHFFFAOYSA-N 0.000 description 1
OKVCKNCXOXSKPO-UHFFFAOYSA-N 1,2,4-triazine-3-carboxylic acid Chemical compound OC(=O)C1=NC=CN=N1 OKVCKNCXOXSKPO-UHFFFAOYSA-N 0.000 description 1
IRRXPOCAMIMYPW-UHFFFAOYSA-N 1,4-dihydroquinazoline-2-carboxylic acid Chemical compound OC(=O)C1=NC2=CC=CC=C2CN1 IRRXPOCAMIMYPW-UHFFFAOYSA-N 0.000 description 1
VHHVWLCQQNAYKN-UHFFFAOYSA-N 1-(2-hydroxyethyl)-3-methyl-5-phenyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound CC1=NN(CCO)C(C(NC2)=O)=C1N=C2C1=CC=CC=C1 VHHVWLCQQNAYKN-UHFFFAOYSA-N 0.000 description 1
SMPHHWPNKCNPMO-UHFFFAOYSA-N 1-(azepan-1-yl)-4-benzyl-7-methyl-[1,2,4]triazolo[4,3-a]quinazolin-5-one;4-benzyl-7-iodo-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C=1C(I)=CC=C(N2C(N3CCCC3)=NN=C22)C=1C(=O)N2CC1=CC=CC=C1.C=1C(C)=CC=C(N2C(N3CCCCCC3)=NN=C22)C=1C(=O)N2CC1=CC=CC=C1 SMPHHWPNKCNPMO-UHFFFAOYSA-N 0.000 description 1
KDZFBRLWAOHCTC-UHFFFAOYSA-N 1-(azepan-1-yl)-7-bromo-4-[(4-chlorophenyl)methyl]-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)C2=CC(Br)=CC=C2N2C(N3CCCCCC3)=NN=C21 KDZFBRLWAOHCTC-UHFFFAOYSA-N 0.000 description 1
CJENGYUQIKXNLB-UHFFFAOYSA-N 1-(azepan-1-yl)-7-chloro-4-[(4-fluorophenyl)methyl]-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=CC(F)=CC=C1CN1C(=O)C2=CC(Cl)=CC=C2N2C(N3CCCCCC3)=NN=C21 CJENGYUQIKXNLB-UHFFFAOYSA-N 0.000 description 1
JSRMTPUEJDOIIP-UHFFFAOYSA-N 1-(cyclobutylmethyl)-3-methyl-5-phenyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound N1=C(C=2C=CC=CC=2)CNC(=O)C2=C1C(C)=NN2CC1CCC1 JSRMTPUEJDOIIP-UHFFFAOYSA-N 0.000 description 1
MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 1
ZVDQOHZQCUEUJS-UHFFFAOYSA-N 1-ethyl-3-methyl-5-[4-(trifluoromethyl)phenyl]-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C)C=2N=C1C1=CC=C(C(F)(F)F)C=C1 ZVDQOHZQCUEUJS-UHFFFAOYSA-N 0.000 description 1
FKUUOQBRNFPMPT-UHFFFAOYSA-N 1-ethyl-3-methyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C)C=2NC1C1=CC=CC=C1 FKUUOQBRNFPMPT-UHFFFAOYSA-N 0.000 description 1
FONOAHPZHXFZPG-UHFFFAOYSA-N 1-ethyl-3-methyl-5-pyridin-4-yl-4,5,6,7-tetrahydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C)C=2NC1C1=CC=NC=C1 FONOAHPZHXFZPG-UHFFFAOYSA-N 0.000 description 1
YMCBEXRFOAXAFX-UHFFFAOYSA-N 1-ethyl-5-(3-hydroxyphenyl)-3-methyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C)C=2N=C1C1=CC=CC(O)=C1 YMCBEXRFOAXAFX-UHFFFAOYSA-N 0.000 description 1
FDGMETLKDISSFF-UHFFFAOYSA-N 1-ethyl-5-(4-hydroxyphenyl)-3-propan-2-yl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C(C)C)C=2N=C1C1=CC=C(O)C=C1 FDGMETLKDISSFF-UHFFFAOYSA-N 0.000 description 1
XUTHQNCLAYREGH-UHFFFAOYSA-N 1-ethyl-5-(4-methoxyphenyl)-3-methyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C)C=2N=C1C1=CC=C(OC)C=C1 XUTHQNCLAYREGH-UHFFFAOYSA-N 0.000 description 1
TZFLRAZGZRQQQB-UHFFFAOYSA-N 1-ethyl-5-phenyl-3-propan-2-yl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C(C)C)C=2N=C1C1=CC=CC=C1 TZFLRAZGZRQQQB-UHFFFAOYSA-N 0.000 description 1
RGERZKVLIURXPY-UHFFFAOYSA-N 11-(2-methyl-4-oxoquinazolin-3-yl)-6-nitro-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound CC1=NC2=CC=CC=C2C(=O)N1C(C(N1CCC=2C=C(C=C3C1=2)[N+]([O-])=O)=O)N=C3C1=CC=CC=C1 RGERZKVLIURXPY-UHFFFAOYSA-N 0.000 description 1
KPINPFHTSGDGHO-UHFFFAOYSA-N 11-(6-bromo-2-methyl-4-oxoquinazolin-3-yl)-6-methyl-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound C=1C(C)=CC=2CCN(C(C(N=3)N4C(C5=CC(Br)=CC=C5N=C4C)=O)=O)C=2C=1C=3C1=CC=CC=C1 KPINPFHTSGDGHO-UHFFFAOYSA-N 0.000 description 1
LMUOPFLPXGNHCL-UHFFFAOYSA-N 11-(6-methoxy-2-methyl-4-oxoquinazolin-3-yl)-6-methyl-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound O=C1C2=CC(OC)=CC=C2N=C(C)N1C(C(N1CCC=2C=C(C)C=C3C1=2)=O)N=C3C1=CC=CC=C1 LMUOPFLPXGNHCL-UHFFFAOYSA-N 0.000 description 1
HVQANRLCVWQRKC-UHFFFAOYSA-N 11-(7-methoxy-2-methyl-4-oxoquinazolin-3-yl)-6-methyl-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound C=1C(OC)=CC=C(C2=O)C=1N=C(C)N2C(C(N1CCC=2C=C(C)C=C3C1=2)=O)N=C3C1=CC=CC=C1 HVQANRLCVWQRKC-UHFFFAOYSA-N 0.000 description 1
FGVLFFGUYNXWKT-UHFFFAOYSA-N 11-[2-(methoxymethyl)-4-oxoquinazolin-3-yl]-6-methyl-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound COCC1=NC2=CC=CC=C2C(=O)N1C(C(N1CCC=2C=C(C)C=C3C1=2)=O)N=C3C1=CC=CC=C1 FGVLFFGUYNXWKT-UHFFFAOYSA-N 0.000 description 1
REKBDMOCNVHHBI-UHFFFAOYSA-N 11-[5-(hydroxymethyl)-2-methyl-4-oxoquinazolin-3-yl]-6-methyl-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound C=1C(C)=CC=2CCN(C(C(N=3)N4C(C5=C(CO)C=CC=C5N=C4C)=O)=O)C=2C=1C=3C1=CC=CC=C1 REKBDMOCNVHHBI-UHFFFAOYSA-N 0.000 description 1
ZWOMUDQWODQGQH-UHFFFAOYSA-N 1H-pyrrolo[2,3-g][1,2]benzodiazepin-2-one Chemical class C1=CC2=NN=CC=CC2=C2C1=CC(=O)N2 ZWOMUDQWODQGQH-UHFFFAOYSA-N 0.000 description 1
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
OGKINOUQUQKXIF-UHFFFAOYSA-N 2-[4-[(7-bromo-5-oxo-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-4-yl)methyl]phenyl]-n-methylacetamide Chemical compound C1=CC(CC(=O)NC)=CC=C1CN1C(=O)C2=CC(Br)=CC=C2N2C(N3CCCC3)=NN=C21 OGKINOUQUQKXIF-UHFFFAOYSA-N 0.000 description 1
FQCIBTVKVAZLCK-UHFFFAOYSA-N 2-[4-[(7-methyl-5-oxo-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-4-yl)methyl]phenyl]acetic acid Chemical compound C=1C(C)=CC=C(N2C(N3CCCC3)=NN=C22)C=1C(=O)N2CC1=CC=C(CC(O)=O)C=C1 FQCIBTVKVAZLCK-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
GSXVPNLAOHBBKA-VWLOTQADSA-N 2-methyl-3-[(11S)-6-methyl-12-oxo-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-11-yl]-4-oxoquinazoline-7-carboxylic acid Chemical compound C=1C(C)=CC=2CCN(C([C@@H](N=3)N4C(C5=CC=C(C=C5N=C4C)C(O)=O)=O)=O)C=2C=1C=3C1=CC=CC=C1 GSXVPNLAOHBBKA-VWLOTQADSA-N 0.000 description 1
125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
OETSJRZSRPIUJQ-UHFFFAOYSA-N 3,5-ditert-butyl-1-ethyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound N1=C(C(C)(C)C)CNC(=O)C2=C1C(C(C)(C)C)=NN2CC OETSJRZSRPIUJQ-UHFFFAOYSA-N 0.000 description 1
DSYROQXOQDRXQF-UHFFFAOYSA-N 3,5-ditert-butyl-1-propyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound N1=C(C(C)(C)C)CNC(=O)C2=C1C(C(C)(C)C)=NN2CCC DSYROQXOQDRXQF-UHFFFAOYSA-N 0.000 description 1
DNYRTYORKRGOOU-UHFFFAOYSA-N 3,5-ditert-butyl-1-propyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepine-8-thione Chemical compound N1=C(C(C)(C)C)CNC(=S)C2=C1C(C(C)(C)C)=NN2CCC DNYRTYORKRGOOU-UHFFFAOYSA-N 0.000 description 1
LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
LQAPQOZOEQHAPS-UHFFFAOYSA-N 3-(6-amino-12-oxo-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-11-yl)-2-methyl-4-oxoquinazoline-7-carboxylic acid Chemical compound CC1=NC2=CC(C(O)=O)=CC=C2C(=O)N1C(C(N1CCC=2C=C(N)C=C3C1=2)=O)N=C3C1=CC=CC=C1 LQAPQOZOEQHAPS-UHFFFAOYSA-N 0.000 description 1
QDPBNMRFDOTINQ-UHFFFAOYSA-N 3-(6-methoxy-12-oxo-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-11-yl)-2-methyl-4-oxoquinazoline-7-carboxylic acid Chemical compound C=1C(OC)=CC=2CCN(C(C(N=3)N4C(C5=CC=C(C=C5N=C4C)C(O)=O)=O)=O)C=2C=1C=3C1=CC=CC=C1 QDPBNMRFDOTINQ-UHFFFAOYSA-N 0.000 description 1
UIVVTPFQVASRRY-UHFFFAOYSA-N 3-(cyclohexylmethyl)-5-phenyl-1-propyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1=2N=C(C=3C=CC=CC=3)CNC(=O)C=2N(CCC)N=C1CC1CCCCC1 UIVVTPFQVASRRY-UHFFFAOYSA-N 0.000 description 1
125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
OVUPYHJKVBHLMW-UHFFFAOYSA-N 3-butan-2-yl-1-ethyl-5-pyridin-4-yl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound CCC(C)C1=NN(CC)C(C(NC2)=O)=C1N=C2C1=CC=NC=C1 OVUPYHJKVBHLMW-UHFFFAOYSA-N 0.000 description 1
BZDVLDVHUYAPON-UHFFFAOYSA-N 3-butyl-1-ethyl-5-phenyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound CCCCC1=NN(CC)C(C(NC2)=O)=C1N=C2C1=CC=CC=C1 BZDVLDVHUYAPON-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical class OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
AAIOFPCMMVSPJN-UHFFFAOYSA-N 3-propan-2-yl-1-propyl-5-(4-pyrrolidin-1-ylphenyl)-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CCC)N=C(C(C)C)C=2N=C1C(C=C1)=CC=C1N1CCCC1 AAIOFPCMMVSPJN-UHFFFAOYSA-N 0.000 description 1
FMDWGNQQWFTIQP-UHFFFAOYSA-N 3-tert-butyl-1-ethyl-5-(4-hydroxyphenyl)-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C(C)(C)C)C=2N=C1C1=CC=C(O)C=C1 FMDWGNQQWFTIQP-UHFFFAOYSA-N 0.000 description 1
DRIDBCHIBBBSFT-UHFFFAOYSA-N 3-tert-butyl-1-ethyl-5-(4-methoxyphenyl)-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C(C)(C)C)C=2N=C1C1=CC=C(OC)C=C1 DRIDBCHIBBBSFT-UHFFFAOYSA-N 0.000 description 1
SPZQULGHYXNVQH-UHFFFAOYSA-N 3-tert-butyl-1-ethyl-5-(4-methylphenyl)-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C(C)(C)C)C=2N=C1C1=CC=C(C)C=C1 SPZQULGHYXNVQH-UHFFFAOYSA-N 0.000 description 1
FMUVIVRWEJMDAH-UHFFFAOYSA-N 3-tert-butyl-1-ethyl-5-phenyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepine-8-thione Chemical compound C1NC(=S)C=2N(CC)N=C(C(C)(C)C)C=2N=C1C1=CC=CC=C1 FMUVIVRWEJMDAH-UHFFFAOYSA-N 0.000 description 1
KRZHHQUNZLUBDF-UHFFFAOYSA-N 3-tert-butyl-5-(2,4-dimethoxyphenyl)-1-ethyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C(C)(C)C)C=2N=C1C1=CC=C(OC)C=C1OC KRZHHQUNZLUBDF-UHFFFAOYSA-N 0.000 description 1
GHPRCQKLLPWZSS-UHFFFAOYSA-N 3-tert-butyl-5-(2,4-dimethoxyphenyl)-1-propyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CCC)N=C(C(C)(C)C)C=2N=C1C1=CC=C(OC)C=C1OC GHPRCQKLLPWZSS-UHFFFAOYSA-N 0.000 description 1
WDZKEWAQIYYMFP-UHFFFAOYSA-N 3-tert-butyl-5-(4-methylphenyl)-1-propyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CCC)N=C(C(C)(C)C)C=2N=C1C1=CC=C(C)C=C1 WDZKEWAQIYYMFP-UHFFFAOYSA-N 0.000 description 1
YIGRZZQZFPQBOK-UHFFFAOYSA-N 4-(1-ethyl-3-methyl-8-oxo-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-5-yl)benzonitrile Chemical compound C1NC(=O)C=2N(CC)N=C(C)C=2N=C1C1=CC=C(C#N)C=C1 YIGRZZQZFPQBOK-UHFFFAOYSA-N 0.000 description 1
SQKPBGUSDKLINS-UHFFFAOYSA-N 4-(3-tert-butyl-1-ethyl-8-oxo-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-5-yl)benzonitrile Chemical compound C1NC(=O)C=2N(CC)N=C(C(C)(C)C)C=2N=C1C1=CC=C(C#N)C=C1 SQKPBGUSDKLINS-UHFFFAOYSA-N 0.000 description 1
PUXIMQBUSFGLJV-UHFFFAOYSA-N 4-(3-tert-butyl-8-oxo-1-propyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-5-yl)benzonitrile Chemical compound C1NC(=O)C=2N(CCC)N=C(C(C)(C)C)C=2N=C1C1=CC=C(C#N)C=C1 PUXIMQBUSFGLJV-UHFFFAOYSA-N 0.000 description 1
JTOMRCCCZBWBJL-UHFFFAOYSA-N 4-(8-oxo-3-propan-2-yl-1-propyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-5-yl)benzonitrile Chemical compound C1NC(=O)C=2N(CCC)N=C(C(C)C)C=2N=C1C1=CC=C(C#N)C=C1 JTOMRCCCZBWBJL-UHFFFAOYSA-N 0.000 description 1
YGOXCHJWJLFWGB-UHFFFAOYSA-N 4-[(4-aminophenyl)methyl]-7-bromo-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=CC(N)=CC=C1CN1C(=O)C2=CC(Br)=CC=C2N2C(N3CCCC3)=NN=C21 YGOXCHJWJLFWGB-UHFFFAOYSA-N 0.000 description 1
NDBPDCRGWPZKIG-UHFFFAOYSA-N 4-[(7-bromo-5-oxo-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-4-yl)methyl]benzonitrile Chemical compound C=1C(Br)=CC=C(N2C(N3CCCC3)=NN=C22)C=1C(=O)N2CC1=CC=C(C#N)C=C1 NDBPDCRGWPZKIG-UHFFFAOYSA-N 0.000 description 1
CLCKZTGFZMUYJI-UHFFFAOYSA-N 4-[[7-bromo-1-(dimethylamino)-5-oxo-[1,2,4]triazolo[4,3-a]quinazolin-4-yl]methyl]benzonitrile Chemical compound O=C1C2=CC(Br)=CC=C2N2C(N(C)C)=NN=C2N1CC1=CC=C(C#N)C=C1 CLCKZTGFZMUYJI-UHFFFAOYSA-N 0.000 description 1
RLZPIYMKOZYBGT-UHFFFAOYSA-N 4-benzyl-7-(propan-2-ylamino)-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C=1C(NC(C)C)=CC=C(N2C(N3CCCC3)=NN=C22)C=1C(=O)N2CC1=CC=CC=C1 RLZPIYMKOZYBGT-UHFFFAOYSA-N 0.000 description 1
TXCFHMBCWUXKRF-UHFFFAOYSA-N 4-benzyl-7-bromo-1-(2,5-dihydropyrrol-1-yl)-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C=1C(Br)=CC=C(N2C(N3CC=CC3)=NN=C22)C=1C(=O)N2CC1=CC=CC=C1 TXCFHMBCWUXKRF-UHFFFAOYSA-N 0.000 description 1
CWLIGHXJDAVVNS-UHFFFAOYSA-N 4-benzyl-7-bromo-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C=1C(Br)=CC=C(N2C(N3CCCC3)=NN=C22)C=1C(=O)N2CC1=CC=CC=C1 CWLIGHXJDAVVNS-UHFFFAOYSA-N 0.000 description 1
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
FYFOYACKSQTJHF-UHFFFAOYSA-N 5-(2,4-dimethoxyphenyl)-1-ethyl-3-propan-2-yl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C(C)C)C=2N=C1C1=CC=C(OC)C=C1OC FYFOYACKSQTJHF-UHFFFAOYSA-N 0.000 description 1
KJWQMWRQEJSAIN-UHFFFAOYSA-N 5-(2,4-dimethoxyphenyl)-3-propan-2-yl-1-propyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CCC)N=C(C(C)C)C=2N=C1C1=CC=C(OC)C=C1OC KJWQMWRQEJSAIN-UHFFFAOYSA-N 0.000 description 1
DDNGGBJHCPULRT-UHFFFAOYSA-N 5-(2,6-dimethoxyphenyl)-1-ethyl-3-methyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C)C=2N=C1C1=C(OC)C=CC=C1OC DDNGGBJHCPULRT-UHFFFAOYSA-N 0.000 description 1
MBYWYHWMUJPUHR-UHFFFAOYSA-N 5-(2-aminophenyl)-1-ethyl-3-methyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C)C=2N=C1C1=CC=CC=C1N MBYWYHWMUJPUHR-UHFFFAOYSA-N 0.000 description 1
FKYYBIZGZWYBFQ-UHFFFAOYSA-N 5-(3-chlorothiophen-2-yl)-1-ethyl-3-methyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C)C=2N=C1C=1SC=CC=1Cl FKYYBIZGZWYBFQ-UHFFFAOYSA-N 0.000 description 1
YSKOUUCQLSBWSC-UHFFFAOYSA-N 5-(4-aminophenyl)-1-ethyl-3-methyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C)C=2N=C1C1=CC=C(N)C=C1 YSKOUUCQLSBWSC-UHFFFAOYSA-N 0.000 description 1
XTBFTFBYVPRMAO-UHFFFAOYSA-N 5-(4-aminophenyl)-1-ethyl-3-propan-2-yl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C(C)C)C=2N=C1C1=CC=C(N)C=C1 XTBFTFBYVPRMAO-UHFFFAOYSA-N 0.000 description 1
GUUNVTVVZFKXSG-UHFFFAOYSA-N 5-(4-aminophenyl)-3-methyl-1-propyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CCC)N=C(C)C=2N=C1C1=CC=C(N)C=C1 GUUNVTVVZFKXSG-UHFFFAOYSA-N 0.000 description 1
BZQVAGJLHAWIQO-UHFFFAOYSA-N 5-(4-aminophenyl)-3-tert-butyl-1-ethyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C(C)(C)C)C=2N=C1C1=CC=C(N)C=C1 BZQVAGJLHAWIQO-UHFFFAOYSA-N 0.000 description 1
ZORAGFXBBKAZQX-UHFFFAOYSA-N 5-(4-bromophenyl)-1,3-dimethyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound CC1=NN(C)C(C(NC2)=O)=C1N=C2C1=CC=C(Br)C=C1 ZORAGFXBBKAZQX-UHFFFAOYSA-N 0.000 description 1
KPUVXZXZLYSBBL-UHFFFAOYSA-N 5-(4-bromophenyl)-1-ethyl-3-methyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C)C=2N=C1C1=CC=C(Br)C=C1 KPUVXZXZLYSBBL-UHFFFAOYSA-N 0.000 description 1
BQXRKJMRGDEPKQ-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-ethyl-3-methyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CC)N=C(C)C=2N=C1C1=CC=C(Cl)C=C1 BQXRKJMRGDEPKQ-UHFFFAOYSA-N 0.000 description 1
KNBOTGBKVJPGGP-UHFFFAOYSA-N 5-(4-methoxyphenyl)-1,3-dimethyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1=CC(OC)=CC=C1C(CNC1=O)=NC2=C1N(C)N=C2C KNBOTGBKVJPGGP-UHFFFAOYSA-N 0.000 description 1
AOJAVTULUWJPBS-UHFFFAOYSA-N 5-(4-methoxyphenyl)-3-propan-2-yl-1-propyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CCC)N=C(C(C)C)C=2N=C1C1=CC=C(OC)C=C1 AOJAVTULUWJPBS-UHFFFAOYSA-N 0.000 description 1
UEKCOHNJLIIPIH-UHFFFAOYSA-N 5-(4-methylphenyl)-3-propan-2-yl-1-propyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1NC(=O)C=2N(CCC)N=C(C(C)C)C=2N=C1C1=CC=C(C)C=C1 UEKCOHNJLIIPIH-UHFFFAOYSA-N 0.000 description 1
RWDKSZKUTHRKKA-UHFFFAOYSA-N 5-(4-methylphenyl)-3-propan-2-yl-1-propyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepine-8-thione Chemical compound C1NC(=S)C=2N(CCC)N=C(C(C)C)C=2N=C1C1=CC=C(C)C=C1 RWDKSZKUTHRKKA-UHFFFAOYSA-N 0.000 description 1
BXOQLFMVWHKBFP-UHFFFAOYSA-N 5-[4-(diethylamino)phenyl]-1-ethyl-3-methyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound C1=CC(N(CC)CC)=CC=C1C(CNC1=O)=NC2=C1N(CC)N=C2C BXOQLFMVWHKBFP-UHFFFAOYSA-N 0.000 description 1
DZWUKPRHDZQYDI-UHFFFAOYSA-N 5-tert-butyl-1-ethyl-3-methyl-4,5,6,7-tetrahydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound N1C(C(C)(C)C)CNC(=O)C2=C1C(C)=NN2CC DZWUKPRHDZQYDI-UHFFFAOYSA-N 0.000 description 1
VLBWSWIXZFSVBY-UHFFFAOYSA-N 5-tert-butyl-1-ethyl-3-propan-2-yl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8-one Chemical compound N1=C(C(C)(C)C)CNC(=O)C2=C1C(C(C)C)=NN2CC VLBWSWIXZFSVBY-UHFFFAOYSA-N 0.000 description 1
IMRFTIAXMNBEJV-UHFFFAOYSA-N 5-tert-butyl-3-propan-2-yl-1-propyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepine-8-thione 1-ethyl-5-(4-methylphenyl)-3-propan-2-yl-6,7-dihydropyrazolo[4,3-e][1,4]diazepine-8-thione Chemical compound C(C)N1N=C(C=2N=C(CNC(C21)=S)C2=CC=C(C=C2)C)C(C)C.C(C)(C)(C)C=2CNC(C1=C(N2)C(=NN1CCC)C(C)C)=S IMRFTIAXMNBEJV-UHFFFAOYSA-N 0.000 description 1
UPZQLUGOLBVHKF-UHFFFAOYSA-N 6-amino-11-(2-methyl-4-oxoquinazolin-3-yl)-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound CC1=NC2=CC=CC=C2C(=O)N1C(C(N1CCC=2C=C(N)C=C3C1=2)=O)N=C3C1=CC=CC=C1 UPZQLUGOLBVHKF-UHFFFAOYSA-N 0.000 description 1
QJWNEJHSZQCMHD-UHFFFAOYSA-N 6-amino-11-(5-chloro-2-methyl-4-oxoquinazolin-3-yl)-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound CC1=NC2=CC=CC(Cl)=C2C(=O)N1C(C(N1CCC=2C=C(N)C=C3C1=2)=O)N=C3C1=CC=CC=C1 QJWNEJHSZQCMHD-UHFFFAOYSA-N 0.000 description 1
KVNDRCVGFXWNFI-UHFFFAOYSA-N 6-methyl-11-(2-methyl-4-oxopteridin-3-yl)-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound C=1C(C)=CC=2CCN(C(C(N=3)N4C(C5=NC=CN=C5N=C4C)=O)=O)C=2C=1C=3C1=CC=CC=C1 KVNDRCVGFXWNFI-UHFFFAOYSA-N 0.000 description 1
YAZFTFZVEWVKPB-UHFFFAOYSA-N 6-methyl-11-(2-methyl-4-oxoquinazolin-3-yl)-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound C=1C(C)=CC=2CCN(C(C(N=3)N4C(C5=CC=CC=C5N=C4C)=O)=O)C=2C=1C=3C1=CC=CC=C1 YAZFTFZVEWVKPB-UHFFFAOYSA-N 0.000 description 1
POLPSAHXNZHDTF-UHFFFAOYSA-N 7-bromo-1-(dimethylamino)-4-[(4-hydroxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound O=C1C2=CC(Br)=CC=C2N2C(N(C)C)=NN=C2N1CC1=CC=C(O)C=C1 POLPSAHXNZHDTF-UHFFFAOYSA-N 0.000 description 1
ZQIRRNCBCSAZJL-UHFFFAOYSA-N 7-bromo-1-(dimethylamino)-4-[(4-methylphenyl)methyl]-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound O=C1C2=CC(Br)=CC=C2N2C(N(C)C)=NN=C2N1CC1=CC=C(C)C=C1 ZQIRRNCBCSAZJL-UHFFFAOYSA-N 0.000 description 1
XNPVCEJETXIYFS-UHFFFAOYSA-N 7-bromo-4-[(3,4-dimethoxyphenyl)methyl]-1-piperidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=C(OC)C(OC)=CC=C1CN1C(=O)C2=CC(Br)=CC=C2N2C(N3CCCCC3)=NN=C21 XNPVCEJETXIYFS-UHFFFAOYSA-N 0.000 description 1
FYQJZDCJAIZTED-UHFFFAOYSA-N 7-bromo-4-[(4-fluorophenyl)methyl]-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=CC(F)=CC=C1CN1C(=O)C2=CC(Br)=CC=C2N2C(N3CCCC3)=NN=C21 FYQJZDCJAIZTED-UHFFFAOYSA-N 0.000 description 1
FOAUHIXXPHKBIO-UHFFFAOYSA-N 7-bromo-4-[(4-hydroxyphenyl)methyl]-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=CC(O)=CC=C1CN1C(=O)C2=CC(Br)=CC=C2N2C(N3CCCC3)=NN=C21 FOAUHIXXPHKBIO-UHFFFAOYSA-N 0.000 description 1
MXQVWLSIDCPTDL-UHFFFAOYSA-N 7-bromo-4-[(4-methoxyphenyl)methyl]-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C2=CC(Br)=CC=C2N2C(N3CCCC3)=NN=C21 MXQVWLSIDCPTDL-UHFFFAOYSA-N 0.000 description 1
OJGXAWBAWJCITA-UHFFFAOYSA-N 7-bromo-4-[(4-nitrophenyl)methyl]-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-5-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1C(=O)C2=CC(Br)=CC=C2N2C(N3CCCC3)=NN=C21 OJGXAWBAWJCITA-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
CNFZEERAPPNIJJ-UHFFFAOYSA-N 9-methoxy-3-(2-methyl-4-oxo-4h-quinazolin-3-yl)-1-phenyl-6,7-dihydro-3h-[1,4]diazepino [6,7,1-hi] indol-4-one Chemical compound COC1=CC=2CCC=C(C(N(C=3)N4C(C5=CC=CC=C5N=C4C)=O)=O)C=2N1C=3C1=CC=CC=C1 CNFZEERAPPNIJJ-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical class CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
BVSNNQFTDMHHHQ-UHFFFAOYSA-N C1CCC(N(CC1)C2=NN=C3N2C4=CC=CC=C4C(=O)N3CC5=CC=CC=C5)N Chemical compound C1CCC(N(CC1)C2=NN=C3N2C4=CC=CC=C4C(=O)N3CC5=CC=CC=C5)N BVSNNQFTDMHHHQ-UHFFFAOYSA-N 0.000 description 1
BURZBQCKZOWCTO-UHFFFAOYSA-N CN(C)C(=O)CC1=CC=C(C=C1)C(N2CCCC2=O)N3CC4=C(C=CC(=C4)Br)N5C3=NN=C5 Chemical compound CN(C)C(=O)CC1=CC=C(C=C1)C(N2CCCC2=O)N3CC4=C(C=CC(=C4)Br)N5C3=NN=C5 BURZBQCKZOWCTO-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical class [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
101100135859 Dictyostelium discoideum regA gene Proteins 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
102100026720 Interferon beta Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241001529936 Murinae Species 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
HRIXRFWGCUWPMA-UHFFFAOYSA-N N=1N=CC2=NC=CNC(C21)=O Chemical compound N=1N=CC2=NC=CNC(C21)=O HRIXRFWGCUWPMA-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 description 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
229920002253 Tannate Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical class [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
239000001639 calcium acetate Chemical class 0.000 description 1
235000011092 calcium acetate Nutrition 0.000 description 1
229960005147 calcium acetate Drugs 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000004041 dendritic cell maturation Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940009662 edetate Drugs 0.000 description 1
229950005627 embonate Drugs 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
229950000206 estolate Drugs 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
150000002168 ethanoic acid esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
XVPYUDCCWQZHGZ-UHFFFAOYSA-N ethyl 1-ethyl-8-oxo-5-phenyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepine-3-carboxylate Chemical compound CCOC(=O)C1=NN(CC)C(C(NC2)=O)=C1N=C2C1=CC=CC=C1 XVPYUDCCWQZHGZ-UHFFFAOYSA-N 0.000 description 1
125000001207 fluorophenyl group Chemical group 0.000 description 1
229940050411 fumarate Drugs 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960001731 gluceptate Drugs 0.000 description 1
KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
229940049906 glutamate Drugs 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
125000004464 hydroxyphenyl group Chemical group 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000017307 interleukin-4 production Effects 0.000 description 1
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
229940099584 lactobionate Drugs 0.000 description 1
JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940049920 malate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
HJGVKGJPMFQKES-UHFFFAOYSA-N methyl 4-[(7-bromo-5-oxo-1-pyrrolidin-1-yl-[1,2,4]triazolo[4,3-a]quinazolin-4-yl)methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1C(=O)C2=CC(Br)=CC=C2N2C(N3CCCC3)=NN=C21 HJGVKGJPMFQKES-UHFFFAOYSA-N 0.000 description 1
ZRQRONZXDFNWHV-UHFFFAOYSA-N methyl 4-[5-bromo-1-(dimethylamino)-5h-[1,2,4]triazolo[4,3-a]quinazoline-4-carbonyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(=O)N1C2=NN=C(N(C)C)N2C2=CC=CC=C2C1Br ZRQRONZXDFNWHV-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
ZHDXBRXIBYUOFM-UHFFFAOYSA-N n-[4-(1-ethyl-3-methyl-8-oxo-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-5-yl)phenyl]acetamide Chemical compound C1NC(=O)C=2N(CC)N=C(C)C=2N=C1C1=CC=C(NC(C)=O)C=C1 ZHDXBRXIBYUOFM-UHFFFAOYSA-N 0.000 description 1
RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
229940014662 pantothenate Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000012466 permeate Substances 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002606 phosphodiesterase VII inhibitor Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
ATQUABCIJINPMX-UHFFFAOYSA-N quinazolin-5-ol Chemical compound C1=NC=C2C(O)=CC=CC2=N1 ATQUABCIJINPMX-UHFFFAOYSA-N 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000005070 ripening Effects 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)

SK1293-2001A 2000-09-15 2001-09-11 Farmaceutická kompozícia na prevenciu alebo liečenie choroby spojenej s nadmernou produkciou IL-12 SK12932001A3 (sk)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP00402560A EP1188438A1 (en)	2000-09-15	2000-09-15	Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production

Publications (1)

Publication Number	Publication Date
SK12932001A3 true SK12932001A3 (sk)	2002-04-04

Family

ID=8173864

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1293-2001A SK12932001A3 (sk)	2000-09-15	2001-09-11	Farmaceutická kompozícia na prevenciu alebo liečenie choroby spojenej s nadmernou produkciou IL-12

Country Status (20)

Country	Link
US (1)	US20020119967A1 (ru)
EP (1)	EP1188438A1 (ru)
JP (1)	JP2002316948A (ru)
KR (1)	KR20020021606A (ru)
CN (1)	CN1348763A (ru)
AR (1)	AR030660A1 (ru)
AU (1)	AU7033201A (ru)
BR (1)	BR0104005A (ru)
CA (1)	CA2357155A1 (ru)
CZ (1)	CZ20013275A3 (ru)
EA (1)	EA200100876A3 (ru)
HU (1)	HUP0103686A2 (ru)
IL (1)	IL145366A0 (ru)
MX (1)	MXPA01009032A (ru)
NO (1)	NO20014414L (ru)
NZ (1)	NZ514107A (ru)
PE (1)	PE20020465A1 (ru)
PL (1)	PL349682A1 (ru)
SK (1)	SK12932001A3 (ru)
WO (1)	WO2002022112A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE332708T1 (de) *	2000-06-06	2006-08-15	Glaxo Group Ltd	Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält
CA2501940A1 (en) *	2002-10-09	2004-04-22	Tolerrx, Inc.	Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use
CN101547922B (zh)	2006-10-04	2012-06-20	辉瑞产品公司	作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物
JP5509099B2 (ja)	2008-03-07	2014-06-04	アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ	新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体並びにそのＭＣＰ−１、ＣＸ３ＣＲ１およびｐ４０の発現に基づく疾患の治療への使用
US8461194B2 (en)	2008-03-07	2013-06-11	Aziende Chimiche Riunite Angelini Francesco A. C. R. A. F. S. P. A.	1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0706513B1 (de) *	1993-07-02	2002-05-15	Byk Gulden Lomberg Chemische Fabrik GmbH	Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
FR2725719B1 (fr) *	1994-10-14	1996-12-06	Jouveinal Inst Rech	Diazepino-indoles inhibiteurs de phosphodiesterases iv
WO1996036626A1 (de) *	1995-05-18	1996-11-21	Byk Gulden Lomberg Chemische Fabrik Gmbh	Cyclohexyldihydrobenzofurane
FR2746800B1 (fr) *	1996-03-29	1998-06-05	Jouveinal Inst Rech	Diazepino-indoles inhibiteurs de phosphodiesterases 4
ATE256476T1 (de) *	1996-11-15	2004-01-15	Kennedy Inst Of Rheumatology	Unterdrückung von tnfalpha und il-12 in der therapie
BR9810409A (pt) *	1997-03-18	2000-08-22	Basf Ag	Métodos e composições para a modulação de responsividade a corticosteróides
FR2762841B1 (fr) *	1997-04-30	1999-07-02	Jouveinal Inst Rech	Diazepino-indolones inhibitrices de phosphodiesterases iv
FR2776660B1 (fr) *	1998-03-27	2000-05-12	Parke Davis	Diazepino-indoles de phosphodiesterases iv
DE19843793C2 (de) *	1998-09-24	2000-08-03	Gruenenthal Gmbh	Substituierte Benzamide
CA2364258C (en) *	1999-03-10	2008-12-30	Byk Gulden Lomberg Chemische Fabrik Gmbh	3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
FR2792938B1 (fr) *	1999-04-28	2001-07-06	Warner Lambert Co	NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
FR2803299B1 (fr) *	2000-01-05	2004-09-17	Warner Lambert Co	NOUVELLES PYRAZOLO [4,3-e] DIAZEPINES SUBSTITUEES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION

2000
- 2000-09-15 EP EP00402560A patent/EP1188438A1/en not_active Withdrawn
2001
- 2001-09-06 MX MXPA01009032A patent/MXPA01009032A/es unknown
- 2001-09-10 EA EA200100876A patent/EA200100876A3/ru unknown
- 2001-09-10 IL IL14536601A patent/IL145366A0/xx unknown
- 2001-09-11 KR KR1020010055998A patent/KR20020021606A/ko not_active Application Discontinuation
- 2001-09-11 CA CA002357155A patent/CA2357155A1/en not_active Abandoned
- 2001-09-11 NZ NZ514107A patent/NZ514107A/xx not_active Application Discontinuation
- 2001-09-11 PE PE2001000914A patent/PE20020465A1/es not_active Application Discontinuation
- 2001-09-11 NO NO20014414A patent/NO20014414L/no unknown
- 2001-09-11 SK SK1293-2001A patent/SK12932001A3/sk unknown
- 2001-09-11 CZ CZ20013275A patent/CZ20013275A3/cs unknown
- 2001-09-12 BR BR0104005-7A patent/BR0104005A/pt not_active Application Discontinuation
- 2001-09-12 CN CN01138457A patent/CN1348763A/zh active Pending
- 2001-09-12 JP JP2001277234A patent/JP2002316948A/ja active Pending
- 2001-09-12 AU AU70332/01A patent/AU7033201A/en not_active Abandoned
- 2001-09-12 AR ARP010104308A patent/AR030660A1/es unknown
- 2001-09-12 HU HU0103686A patent/HUP0103686A2/hu unknown
- 2001-09-13 WO PCT/EP2001/010590 patent/WO2002022112A2/en active Search and Examination
- 2001-09-14 PL PL01349682A patent/PL349682A1/xx not_active Application Discontinuation
- 2001-09-15 US US09/953,822 patent/US20020119967A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EA200100876A3 (ru)	2002-06-27
AU7033201A (en)	2002-03-21
EP1188438A1 (en)	2002-03-20
IL145366A0 (en)	2002-06-30
WO2002022112A9 (en)	2002-06-06
WO2002022112A3 (en)	2004-02-26
AR030660A1 (es)	2003-08-27
NO20014414L (no)	2002-03-18
NO20014414D0 (no)	2001-09-11
US20020119967A1 (en)	2002-08-29
CZ20013275A3 (cs)	2002-04-17
EA200100876A2 (ru)	2002-04-25
JP2002316948A (ja)	2002-10-31
CA2357155A1 (en)	2002-03-15
HUP0103686A2 (en)	2002-06-29
WO2002022112A2 (en)	2002-03-21
CN1348763A (zh)	2002-05-15
KR20020021606A (ko)	2002-03-21
PL349682A1 (en)	2002-03-25
PE20020465A1 (es)	2002-06-06
HU0103686D0 (en)	2001-11-28
NZ514107A (en)	2001-09-28
BR0104005A (pt)	2002-07-09
MXPA01009032A (es)	2004-11-10

Publication	Publication Date	Title
US11464781B2 (en)	2022-10-11	PDE1 inhibitors for ophthalmic disorders
US9006258B2 (en)	2015-04-14	Method of treating female sexual dysfunction with a PDE1 inhibitor
US9198924B2 (en)	2015-12-01	Organic compounds
JPH08259567A (ja)	1996-10-08	ピラゾロピリミジン類およびピロロピリミジン類によるニューロン疾患およびその他疾患の治療方法
AU2005274852A1 (en)	2006-02-23	FLT3 inhibitors for immune suppression
JP2010511616A (ja)	2010-04-15	水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法
UA77329C2 (en)	2006-11-15	Combination of alpha-2-delta ligand and a pdev inhibitor for use in therapy of pain
JP2008520747A (ja)	2008-06-19	アデノシンａ３受容体アゴニストを用いたｈｉｆ−１が介在する疾患の促進的治療
WO2006018088A1 (en)	2006-02-23	Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders
EP1199074A1 (en)	2002-04-24	Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1494650B1 (en)	2011-05-04	Pharmaceutical formulation comprising melatonin
SK12932001A3 (sk)	2002-04-04	Farmaceutická kompozícia na prevenciu alebo liečenie choroby spojenej s nadmernou produkciou IL-12
JP2006527257A (ja)	2006-11-30	月経困難症の治療用のｐｄｅ阻害剤及びバソプレッシン受容体アンタゴニストを含んでなる療法組合せ
MX2011003347A (es)	2011-05-25	Metodos para reducir celulas t, b-auxiliares para tratar enfermedades autoinmunes.
Klegeris et al.	2000	Inhibitory action of 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide (PK 11195) on some mononuclear phagocyte functions
Hegde et al.	2010	To market, to market—2009
US20240156825A1 (en)	2024-05-16	Use of selective vegfr2 and fgfr1 inhibitors
Greenwald et al.	2011	JAK: no longer'just another kinase'
Chan et al.	2010	Inhibitors Targeting JAK3
Maldonado et al.	2011	Canakinumab for the treatment of gout
Takeuchi et al.	2013	Safety, tolerability, pharmacokinetics and pharmacodynamics of E3024, a novel and selective Dipeptidyl peptidase-IV inhibitor, in healthy Japanese male subjects: rash development in men and its possible mechanism
Gram	2014	Canakinumab (ILARIS®)